| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Introduction
Non-Hodgkin's lymphoma, consisting of 29 different malignancies of the
lymphatic system, is a devastating disease: although treatable, only a small
percentage of these cancers are curable, and median survival of aggressive
NHLs is poor. While treatment has greatly improved since the introduction of
Genentech's Rituxan in 1997, considerable unmet treatment needs remain,
spurring signifi cant development in NHL therapies
Get the Answers You Need to Shape Your Strategy
Genentech's Rituxan has generated strong growth in the NHL market since its
launch, although Rituxan's market penetration may have peaked. What factors
will drive future growth in the NHL market? Where do opportunities lie in the
treatment of NHL? How will emerging agents stack up against Rituxan? With
the launch of new agents, cost will become a driving factor in NHL treatment.
Which emerging therapies or drug classes will command the highest prices in
the NHL market? How will third-party payers respond to the arrival of potent
but potentially expensive NHL therapies? As many as 20 new therapies are
in development for the treatment of NHL. Where will new therapies that
arrive on the market fi t alongside existing treatment regimens for NHL? What
types of NHL will benefi t most from new therapies? How will these agents be
positioned in the market? What present agents, if any, will face
competition?
Scope
- Overview of non-Hodgkin's lymphoma: disease characteristics, risk factors,
classification and staging, and diagnosis and prevalence
- Lymphomas covered: follicular lymphoma, B-cell lymphomas, T-cell
lymphomas, mantle cell lymphoma
- Current therapies: overview of agents currently in use to treat NHL
- Emerging therapies: a review of leading agents in development for NHL
- Drug classes covered: novel chemotherapy agents, combination therapies,
vaccines, monoclonal antibodies, radioimmunotherapies
- Market outlook: our projections for how emerging agents could alter the
NHL landscape
Companies Mentioned in This Spectrum Report
- Accentia Biopharmaceuticals
- Amgen
- Baxter
- Biogen Idec
- BioVest International
- Bristol-Myers Squibb
- Celgene
- Cephalon Oncology
- Chugai
- EG Labo
- Eli Lilly
- Enzon Pharmaceuticals
- Favrille
- Fujisawa Deutschland
- Genentech
- Genitope
- Genmab
- GlaxoSmithKline
- Gloucester Pharmaceuticals
- Hana Bioscience
- Human Genome Sciences
- Immunomedics
- Inex Pharmaceuticals
- Kyowa
- Large Scale Biologics
- Merck
- Millennium Pharmaceuticals
- Pfizer
- Roche
- Seattle Genetics
- Wyeth
TABLE OF CONTENTS
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Non-Hodgkin's Lymphoma
- Disease Characteristics and Risk Factors
- Disease Classification, Staging, and Grade
- Diagnosis and Prevalent and Incident Cases
- Current Therapies
- Emerging Therapies
- Novel Chemotherapy Agents
- Hana Bioscience's Marquibo
- Cephalon's Treanda
- Agents for Use in Combination with Rituxan
- Vaccines
- Genentech/Roche/Chugai's Avastin
- Immunomedics' Epratuzumab
- Biogen Idec's Galiximab
- Celgene's Revlimid
- Agents in Development for T-Cell Lymphomas
- Gloucester Pharmaceuticals' Romidepsin
- Seattle Genetics' SGN-30
- Agents in Development for Mantle Cell Lymphoma
- Wyeth's Temsirolimus
- Genta's Genasense
- Millennium Pharmaceuticals' Velcade
- Agents in Development for Relapsed or Refractory NHL
- Genmab's HuMax-CD20
- Eli Lilly's Enzastaurin
- Other Agents in Development
- Human Genome Sciences/GlaxoSmithKline's Mapatumumab
- Outlook for the NHL Market
Tables:
- 1. Descriptions of Common Types of Non-Hodgkin's Lymphomas
- 2. The WHO Classification System for Non-Hodgkin's Lymphoma
- 3. Lymphoma Staging System: Ann Arbor Classification
- 4. Current Therapy Regimens for Non-Hodgkin's Lymphoma
- 5. Select Agents in Development for Non-Hodgkin's Lymphoma
Figures:
- 1. Prevalent and Incident Cases of Non-Hodgkin's Lymphoma, 2005
- 2. Number of Agents in Development by Strategy
|
